Business Description
IN8bio Inc
NAICS : 325412
SIC : 2834
ISIN : US45674E1091
Share Class Description:
INAB: Ordinary SharesDescription
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.73 | |||||
| Equity-to-Asset | 0.54 | |||||
| Debt-to-Equity | 0.64 | |||||
| Debt-to-EBITDA | -0.19 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -28.8 | |||||
| 3-Year EPS without NRI Growth Rate | -23.4 | |||||
| 3-Year FCF Growth Rate | -29.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 31.93 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.27 | |||||
| 9-Day RSI | 41.6 | |||||
| 14-Day RSI | 44.39 | |||||
| 3-1 Month Momentum % | 0.06 | |||||
| 6-1 Month Momentum % | -81.15 | |||||
| 12-1 Month Momentum % | -77.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.84 | |||||
| Quick Ratio | 1.84 | |||||
| Cash Ratio | 1.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -30.6 | |||||
| Shareholder Yield % | -66.36 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -193.35 | |||||
| ROA % | -128.6 | |||||
| ROIC % | -259.19 | |||||
| 3-Year ROIIC % | -243.87 | |||||
| ROC (Joel Greenblatt) % | -337.24 | |||||
| ROCE % | -154.03 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.58 | |||||
| Price-to-Tangible-Book | 1.58 | |||||
| EV-to-EBIT | -0.72 | |||||
| EV-to-EBITDA | -0.78 | |||||
| EV-to-FCF | -0.89 | |||||
| Earnings Yield (Greenblatt) % | -138.89 | |||||
| FCF Yield % | -122.04 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:INAB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
IN8bio Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.75 | ||
| Beta | -0.04 | ||
| 3-Year Sharpe Ratio | -0.52 | ||
| 3-Year Sortino Ratio | -0.81 | ||
| Volatility % | 102.54 | ||
| 14-Day RSI | 44.39 | ||
| 14-Day ATR ($) | 0.037446 | ||
| 20-Day SMA ($) | 0.314635 | ||
| 12-1 Month Momentum % | -77.85 | ||
| 52-Week Range ($) | 0.217 - 2.48 | ||
| Shares Outstanding (Mil) | 72.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
IN8bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
IN8bio Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
IN8bio Inc Frequently Asked Questions
What is IN8bio Inc(INAB)'s stock price today?
The current price of INAB is $0.28. The 52 week high of INAB is $2.48 and 52 week low is $0.22.
When is next earnings date of IN8bio Inc(INAB)?
The next earnings date of IN8bio Inc(INAB) is 2025-03-14 Est..
Does IN8bio Inc(INAB) pay dividends? If so, how much?
IN8bio Inc(INAB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers